Bevacizumab treatment in hereditary hemorrhagic teleangiectasia

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1685-1686

  Föllner, Sebastian ^a   Ibe, Michael ^b   Schreiber, Jens ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Clinic for Internal Medicine II Südharzklinikum Nordhausen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BEVACIZUMAB; HEMOGLOBIN; VASCULOTROPIN;

ADULT; AGED; ANTIBODY PRODUCTION; BLOOD TRANSFUSION REACTION; CASE REPORT; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMED CONSENT; LASER SURGERY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; NOSE MUCOSA; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RENDU OSLER WEBER DISEASE; TISSUE TRANSPLANTATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; PHARMACOVIGILANCE;

EID: 84871318269     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1308-4     Document Type: Letter

References (10)

1. Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor M-J (2012) Bevacizumab-induced serious side-effects: a review of French pharmacovigilance database. Eur J Clin Pharmacol. doi:10.1007/s00228-012-1232-7
2. Simonds J, Miller F, Mandel J et al (2009) The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119:988
3. Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85:631-632
4. Mitchell A, Adams LA,MacQuillan G, Tibballs J, vanden Driesen R (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplant 14:210-213
5. Cirulli A, Liso A, D'Ovidio F, Mestice A, Pasculli G, Gallitelli M, Rizzi R, Specchia G, Sabbà C (2003) Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 110(1):29-32
6. Giordano P, Lenato GM, Pierucci P, Suppressa P, Altomare M, Del Vecchio G, Di Bitonto G, De Mattia D, Guanti G, Sabbà C (2009) Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. J Pediatr Hematol Oncol 31(8):577-582
7. Buscarini E, Manfredi G, Zambelli A (2008) Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl 14(11):1685-6, author reply 1687-1688
8. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14:210-213
9. Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143- 2144
10. Pasche B, Wollstein AC, Zoll B, Folz B (2003) Rendu-Osler-Weber Syndrom. Dtsch Ärztebl 100(8):A490-A493